BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Express Scripts
Argus Health
Harvard Business School

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,132,766

« Back to Dashboard

Summary for Patent: 6,132,766

Title: Multivesicular liposomes with controlled release of encapsulated biologically active substances
Abstract:A multivesicular liposome composition containing at least one acid other than a hydrohalic acid and at least one biologically active substance, the vesicles having defined size distribution, adjustable average size, internal chamber size and number, provides a controlled release rate of the biologically active substance from the composition. A process for making the composition features addition of a non-hydrohalic acid effective to sustain and control the rate of release of an encapsulated biologically active substance from the vesicles at therapeutic levels in vivo.
Inventor(s): Sankaram; Mantripragada Bhima (San Diego, CA), Kim; Sinil (Solana Beach, CA)
Assignee: SkyePharma Inc. (San Diego, CA)
Application Number:09/045,236
Patent Claim Types:
see list of patent claims
Use; Dosage form; Device;

No matches for this query

International Patent Family for Patent: 6,132,766

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria196248► Subscribe
Australia686277► Subscribe
Australia1053595► Subscribe
Bulgaria100596► Subscribe
Bulgaria63146► Subscribe
Brazil9408072► Subscribe
Canada2176712► Subscribe
China1140989► Subscribe
China1099868► Subscribe
Germany69425901► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Boehringer Ingelheim
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: